Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib Presented ByProf. Lars Erik Kristensen , Copenhagen University Hospital, Denmark ConferenceEULAR 2022 21 July, 2022 17:30